Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) Technology appraisal guidance [TA240] – NICE

NICE is unable to recommend panitumumab with 5‑fluorouracil, folinic acid and irinotecan (FOLFIRI) for previously treated metastatic colorectal cancer in adults because no evidence submission was received from the manufacturer or sponsor of the technology.

Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal): Technology appraisal guidance [TA438] – NICE

NICE is unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer previously treated with crizotinib because no evidence submission was received from Roche. We will review this decision

Cetuximab and panitumumab for previously untreated metastatic colorectal cancer: Technology appraisal guidance [TA439] – NICE

Evidence-based recommendations on cetuximab (Erbitux) and panitumumab (Vectibix) for previously untreated RAS wild-type metastatic colorectal cancer in adults. This guidance replaces NICE technology appraisal guidance on cetuximab for the first-line treatment of metastatic colorectal cancer (TA176). This guidance partially updates

Public satisfaction with the NHS and social care in 2016: Results and trends from the British Social Attitudes survey – King’s Fund

The British public’s satisfaction with the NHS remained steady in 2016, according to the data contained in this report. The findings from the British Social Attitudes survey, carried out by the National Centre for Social Research between July and October

Improving accountability in the provision of new models of care: Winter Review Report – National Association of Primary Care

Report focused on population budgets and new metrics for new models of care particularly in relation to the Primary Care Home. Population budgets start from the premise that the patient populations determine what services are needed and how those services are

Skills for Health working paper 2: How we can act now to create a high quality support workforce in the UK’s health sector – Skills for Health

Paper that argues whilst the support workforce requires more skills development, this development needs to be an integral part of an organisation’s workforce development strategy and be accompanied by the development of high quality roles. Using skills that have been

Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal): Technology appraisal guidance [TA437] – NICE

NICE was unable to make a recommendation about the use in the NHS of ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy because no evidence submission was received from Janssen-Cilag, but will

Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal): Technology appraisal guidance [TA436] – NICE

NICE was unable to make a recommendation about the use in the NHS of bevacizumab for treating epidermal growth factor receptor mutation-positive non-small-cell lung cancer because no evidence submission was received from Roche, but will review this decision if the

Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women: Interventional procedures guidance [IPG576] – NICE

Evidence-based recommendations on extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women. This involves putting 2 small balloons on either side of the tube that carries urine from the bladder to support it and reduce leaks. This guidance

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer: Clinical guideline [CG164] – NICE

This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote